Relay Therapeutics, Inc.

Relay Therapeutics Misses on Revenue, Stock Up 1.27%

Relay Therapeutics reported a wider-than-expected loss per share, but the stock still saw a modest increase of 1.27%. This uptick may reflect investor optimism despite the lack of revenue figures and guidance. The market's reaction suggests some confidence in the company's future potential, even without detailed commentary from management.